Network members

More information to come!

Alligator Bioscience AB discovers and develops antibody-based drugs for immunotherapy of cancer. The pipeline comprises mono- and bispecific compounds for tumor-directed immunotherapy in pre-clinical and early clinical development.
In drug discovery, Alligator uses its proprietary technology platforms, the fully human antibody library, ALLIGATOR-GOLD®, and the protein optimization technology, FIND®.
Alligator was founded in 2001 and is located at Medicon Village in Lund. The company is listed on Nasdaq Stockholm.

Network objective
Alligator welcomes collaboration opportunities with biotech and academia. Our main areas of interest include novel modes of action in immuno-oncology as well as innovative strategies for tumor-localized immune activation, and partnerships may be in the form of in-licensing or co-development.

Contact: Eva Dahlén, Senior Director, Business Development: evd [at]

Bioneer A/S is a Danish research-driven advanced technology company with a broad portfolio of technologies and know-how within biomedicine and biotechnology. Our main focus areas are Molecular Histology & Detection, Human Disease Models, Pharmaceutical Formulation & Characterization, and Recombinant Protein Production. Bioneer is a Center of Excellence in advanced mRNA, lnRNA and microRNA ISH. We provide customized services relevant for the oncology field such as RNA ISH, multiplex and immunological analyses. We welcome partnerships both on a commercial basis as well as joint R&D projects.

Network objective:
To discuss current topics within the oncological field; to retain knowledge about the latest trends and breakthroughs within oncology; to showcase Bioneer’s strengths in the field; and, to identify collaboration projects in oncology. 

Contact: Lovisa Sunesson, Sales & Business Development: lms [at]; Boye Schnack Nielsen, Business and Research Manager, Molecular Histology: bsn [at]

COBIS A/S is an ambitious center of growth, creating the right conditions for the life science successes of tomorrow. COBIS has something to offer you regardless of whether you represent an established life science or biotech company, a CRO within life science, or even if you simply have a good idea and need help to get started. With +90 companies we are the largest cluster of life science startups in Denmark.

Network objective:
To support the community for oncology startups in the region by providing access to state-of the-art offices and labs, development programs and pre-seed funding.

Contact: Morten Mølgaard Jensen, CEO: mmj [ at ]


CREATE Health is a Translational Cancer comprised of scientist and clinicians from four faculties at Lund University.

Using advanced “omics” technologies the aim is to solve problems identified in cancer clinics, both nationally and internationally. CREATE Health has a vast network of collaborative institutions, found in e.g. Oxford, NYC, Tianjin (China), Madrid etc.

 Network objective: 
Our main objective for this network is to increase awareness of cutting-edge companies/research and to promote collaborative efforts and M&A in this area.

Contact: Prof. Carl Borrebaeck, Director: carl.borrebaeck [ at ]
 Ulrika Axelsson, Deputy Director: ulrika.axelsson [ at ]

DANSK BIOTEK is a non-for-profit trade organisation aimed to ensure the best possible framework for research, development, and production for the biotechnology companies in Denmark. We work politically to improve the conditions for life-science ecosystem; especially medical biotech innovation, and we organize 4 major meetings for our members to increase knowledge-sharing regarding specific biotech topics and to facilitate networking. We also organize smaller “meet-the-expert” meetings advocating more in-depth discussions.

Network objective:
– Increase the knowledge of modern biotechnology in the public
– Impact on the political agenda regarding the use of biotechnology and improve the framework conditions
– Create the best conditions in Denmark for the members’ research and development activities as well as production
– Promote the members’ interests – nationally and internationally

Contact: Kaya Plewnia, Front Office Manager: kp [ at ]


HØIBERG: It is all about trust. We strive to be the trustworthy IP partner doing what it takes to secure your rights. HØIBERG focuses on predicting the IP needs of companies and preparing a future-proof protection for their inventions and trademarks in accordance with their business needs. HØIBERG collaborates with a wide range of national and international companies and organizations, and ensures that they get the most out of their ideas and products and thereby create and maintain new business opportunities.

Network objective:
To discuss and share new knowledge in the field of oncology, and to contribute in sharing knowledge about how to secure patents on oncology inventions so that new knowledge can be commercialized to the benefit of patients.

Contact: Jens Viktor Nørgaard, Partner & European Patent Attorney: jvn [ at ]

Immunitrack ApS has key capabilities that may apply within the field of Immuno-oncology.  We are specialized in synthesis of MHC complex reagents for isolation of tumor specific T cells, and in vitro peptide binding assays that eliminate inaccuracies in traditional epitope prediction software such as netMHC. Our expertise has been validated through more than a decade of academic research and we are acknowledged as experts in this field.

Network objective:
We are looking for customers for our products and services, collaborators with access to clinical data for further validation of our platform, or with interest in developing bi-specific antibodies targeting tumor specific MHC/epitope complexes.

Contact: Stephan Thorgrimsen, CEO: sthor [ at ]


Junvik Clinical Development Consulting AB is a Clinical Research Organisation based in Malmö, Sweden. We can provide support within clinical development for pharmaceutical or biotech companies, Clinical Research Organizations ​and Universities.
We are experience in all development phases, with expertise in early development, both small molecules and biologics.​​ Therapeutic areas include Oncology, Autoimmune diseases, Haemostasis, Medical devices, Diabetes and Infectious diseases.

Network objective:
To extend our oncology network in the MVA region, i.e. initiate new relations with pharma, biotechs, and other CROs, for potential business opportunities. Our aim is also to continuously learn and build on our oncology expertise in a field that is constantly changing and emerging.  

Contact: Christina Junvik, Directing Manager: christina [ at ]

Larix A/S is a full-service Nordic CRO with offices in Medical Valley offering assistance in all aspects of clinical trials (studies). Our highly motivated and professional staff has experience in clinical development within oncology medicinal products, – and devices. Larix provides you with flexible solutions tailored to your needs, e.g. we can support a full service study or you can outsource specific tasks and/or in-source a consultant part/full time. Our customers are companies  from the smallest biotech/medical device to the major pharmaceutical companies.

Network objective:
To support and collaborate within the network with our expertise, and to move the pharmaceutical and medical device oncology industry forward with a high quality. To build sustainable cooperation’s through all phases.

Contact: Dorthe Grønnegaard Mejer, Vice President, Clinical Development: dgm [ at ]  

LU Innovation is the hub for innovation and commercialization at Lund University. We work with the University’s researchers and students to bring benefit and growth to society.

Our goal and mission is to contribute to increased growth in Sweden by ensuring knowledge and research from Lund University benefit society. By supporting and developing research findings with researchers and students we work to lead more ideas to company formations and/or licensing deals.

Network objective:
To have a regional platform for exchanging ideas relating to cancer research.

Contact: Johanna Asklin, Innovation Manager: johanna.asklin [at]

Medeon Science Park & Incubator provides a creative environment for new and established companies. More than 60 businesses, with over 450 employees are connected to the science park. Our focus is directed at knowledgeintensive businesses within life science: pharmaceutical development, medical technology, biotechnology and health care. The location is in Malmö, right at the centre of the Öresund region and bang in the middle of Medicon Valley – the geographical area which is home to most of Scandinavia’s life science firms.

Network objective:
It’s one important piece in the process of helping our companies in their development phase and also an excellent enlargement of our networks.

Contact: Ulf G Andersson, CEO: ulf.g.andersson [ at]
Catrine Pauckstadt, Communications Manager: catrine.pauckstadt [ at]


Medicon Valley Alliance (MVA) is a non-profit membership organization in the Danish-Swedish life science cluster Medicon Valley. Our 240+ members include the region´s leading universities, hospitals, and private sector life science industry. MVA serves as the regional life science professional “market place” for the exchange of knowledge, networks and contacts and we create value for our members by hosting, promoting and facilitating meetings, networks, events, and projects, that serve to strengthen professional collaboration in the regions life science eco-system.

Network objective:
Bring together industry, academia and health care to stimulate development, commercialization and growth within the region’s oncology system.

Contact: Helen Pettersson, Senior Project Manager: hp [ at ]

PRA Health Sciences is a world leading global CRO offering outsourced clinical development services to biotechnology and pharmaceutical industries and is comprised of 13,000 employees across 70+ offices worldwide. As a recognized leader in conducting complex, global oncology/hematology trials, PRA has contributed to the approval of 15 important drugs. During the last five years, PRA has participated in more than 400 oncology and hematology clinical projects globally in every phase and virtually every indication, including supportive care.

Network objective:
PRA Health Sciences is committed to moving drug discovery forward. Working side-by-side with our partners across the life sciences sector we help develop life-saving and life-improving drugs.

Ingegerd Dalfelt, Senior Manager, Clinical Operations Scandinavia: DalfeltIngegerd [ at ]


Spago Nanomedical AB develops nanomaterials for diagnosis and therapy of cancer. SpagoPix, with product candidate SN132D, is a tumor selective contrast agent with exceptional signal strength for MRI diagnosis of cancer. Tumorad is a radionuclide therapy for treatment of solid tumors. Based on our proprietary nanoparticles and expert capabilities in chemistry and nanomedicine we aim to develop our projects into clinical trials prior to outlicensing or strategic partnering for further development to registration and commercialization.  

Network objective:
To interact and exchange information regarding collaborations, business opportunities, and science in order to facilitate project development within our company and others.

Contact: Mats Hansen, CEO 


Taconic Biosciences has been a leading provider of research models for over 60 years. Through all six decades, we’ve had a singular mission—to create a difference in human health by providing the best, most relevant mouse and rat models to researchers in the life science community.

Network objective:
Modern oncology, infectious disease, and immunology research requires specialized mouse models. We have several of these models and are looking for partners to collaborate with using them in new ways within the Oncology field.

Contact: Anne Edenro, Strategic Account Manager: anne.edenro [ at ]

At Section for Molecular Disease Biology/Translational Cancer Research at Institute of Drug Design and Pharmacology, University of Copenhagen, we develop cancer biomarkers and novel ways to treat cancer. The two major interests are: Preventive Cancer medicine and Targeting Drug Resistance Mechanisms.

Network objective:
We wish collaboration with other cancer researchers, biotech companies and pharma Industry within cancer treatment as well as organizations dealing with patent issues and clinical trials. In particular, we wish contact with companies being at an early stage anti-cancer drug development.

Contact: Prof. Nils Brünner: nbr [ at ]

World Courier is a global specialty logistics company that designs world-class logistics and supply chain programs in complete alignment with our customers’ business goals. Pharmaceutical companies rely on us because they value the peace of mind that comes with our unsurpassed knowledge, global reach and flawless supply chain execution.

With 2,000+ associates in more than 140 offices across the globe, we offer solutions that instill confidence in the on-time, on-temperature delivery of high-value products.

Network objective:
World Courier wishes to participate in the network to meet new partners. We aim to support the knowledge transfer in specialized logistics and enhance the discussion on logistical and regulatory challenges companies face when conducting clinical trials in oncology and shipping valuable clinical samples.

Contact: Simon Nord, Key Account Manager: snord [ at ]